PMID: 11332153May 3, 2001Paper

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566

Annals of Oncology : Official Journal of the European Society for Medical Oncology
C ErlichmanR Humphrey

Abstract

Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis and have been implicated in breast, ovarian, colorectal, and lung cancer growth. We undertook a phase I study of BAY 12-9566, an inhibitor of MMP-2, MMP-9, and MMP-3, in patients with solid tumors to determine its safety, pharmacokinetics, and effects on potential surrogate markers of biologic activity. BAY 12-9566 was orally administered daily at four dose levels; 400 mg daily, 400 mg b.i.d., 400 mg t.i.d., and 800 mg b.i.d. Drug disposition was determined on days 1 and 29 with weekly trough levels measured during the first four weeks. Plasma vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and urinary pyridinoline and deoxypyridinoline crosslinks were determined at baseline, once weekly for four weeks, and then every four weeks. Thirteen patients were entered on trial. BAY 12-9566 was well tolerated, with only one grade 3 headache, one grade 3 anemia, one grade 3 thrombocytopenia, and no musculoskeletal effects. The median treatment duration was 57 days (range 7-560). Mean trough levels of BAY 12-9566 on day 28 ranged from 80.5 to 108.6 mg/l. Plasma trough levels were 1500-42,000-fold above the Ki's for MMP-2, MMP-3...Continue Reading

Citations

Jun 1, 2001·Nature Medicine·C BremerR Weissleder
Feb 24, 2004·Journal of Cellular Physiology·Cristina MorelliMauro Tognon
Jun 17, 2005·Expert Opinion on Pharmacotherapy·Fiona BlackhallNicholas Thatcher
Nov 29, 2012·The Cancer Journal·Pelin Cinar, Margaret A Tempero
Mar 30, 2002·Annals of Surgery·Peter BalazMarkus W Büchler
Jun 4, 2004·Expert Opinion on Investigational Drugs·Nabil Saba, Fadlo Khuri
Feb 3, 2007·Current Opinion in Oncology·Fiona H Blackhall, Frances A Shepherd
Jun 18, 2002·Pharmacotherapy·Michelle A RudekWilliam D Figg
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jul 16, 2005·Experimental Lung Research·Subhadeep Chakrabarti, Kamala D Patel
Jun 17, 2011·The Journal of Biological Chemistry·Aditi BanerjeeDipak K Banerjee
Sep 30, 2006·Arthritis and Rheumatism·Aruna K BeheraLinden T Hu
Mar 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kathy D MillerGeorge W Sledge
Jan 6, 2021·Pharmaceuticals·Nabangshu DasAntoine Dufour
Apr 22, 2021·Nature Reviews. Nephrology·Justyna WozniakAndreas Ludwig
Jun 23, 2021·European Journal of Medicinal Chemistry·Sanjib DasTarun Jha
Apr 12, 2003·Neuroimaging Clinics of North America·Michael J Fisher, Peter C Adamson
Nov 16, 2021·Future Medicinal Chemistry·Haili LinMingdong Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.